Nektar Therapeutics (NKTR)

I'm gambling here. My guess is based on a friend of a friend.

The stock price is up 33% over the last year in spite of these terrible #s: Price/Cash Flow = -42.8 Rev. Gwth.
(Last vs. Prior TTM)= -67.0% Profit Margin = -38.1% Ret. on Invest. (TTM) = -7.4% Current Ratio = 5.9
I expect they will use up the money in the bank and struggle to get more.

I just noticed how outdated all of the pitches for and against NKTR are. The Exubera debacle is behind them, and people are just waking up to the notion that this is a different company with a bright future.

There are a lot of positives here: The burn rate has been cut. A recent partnership with Bayer for inhaled Amikacin had very favorable terms. The sale of the pulmonary arm of the company minus some of the most advanced candidates to NVS strengthened NKTR's financial position, and cost them little. Perhaps most importantly, the power and value of their PEGylation platform is just now starting to get some of the attention it deserves. NKTR-102, NKTR-105, NKTR-118, NKTR-119. These are the proprietary drug candidates that could make anybody buying NKTR in the current price range a very happy camper in 3-5 years. NKTR-102, PEG irinotecan, is already showing convincing signs of substantial improvement over the unmodified parent molecule. This combined with the revenue stream expected from the partnered products makes NKTR an extremely undervalued company that few have noticed in the wreckage of the larger market.

Turn around already!

Because Pfizer want to stop sell the product(inulin inhaler) with NKTR, and the stock got plunge down hard by about 25%. But it will search for another partner to continue sell the product. It might be down for awhile, but I will come back up.

NKTR will outperform their shares in the next two q'S?

NKTR will focus on PEGylation. A technology that should pharmaceutical companies will fall in love with to keep their drugs on patent longer.

APPLIC OF MEDS THROUGH LUNGS --- ???

On e plus side, NKTR has a solid and experienced management tean in place and a successful track record of developing products.

On the minus side, the new CEO is untried in the current situation and it remains to be seen if he can find the right strategy to guide NKTR out of the woods.

At under $6, NKTR has a lot of upside potential.

NKTR has already been taken to the woodshed for the Exubera debacle. When the dust settles the relatively strong pipeline, and the underlying technology should get the attention they deserve. The recent Bayer deal, a solid positive, has been overshadowed by Pfizer's move to drop Exubera.

early pipeline gaining visibility,good news flow in the past couple of weeks

Diabets help with more marketing exposure

Effect on Lungs still better than the needle.

This is a turnaround time for NKTR. S&P 500 already grew to its heights this year and I don't think it is going go for ever. NKTR has good produt pipe line and Phase II studies for couple of own products are due by DEC.

Unique and attractive delivery method for Exubera. Robust product pipeline.

PFE is finally pumping some dollars to advertise Exubera.

NKTR has many other product other than Exubera, so it Exubera can sells for 700M, NKTR should be trading at $16-$19, anything else is free bonus.

Also, you have got to love the value, as I sold it at $24 after all the Exubera hype, not I can buy it back at 60% off, what is not to love

The first on the market with this technology, and royalties from Pfizer. Name recognition, fear of needles, obesity epidemic.

inhalable insuline . no needles

A new delivery system will likely be talked down by manufacturers of old line therapies and insurance reimbursement unless patients find it is easier and better. That children cannot and should not use it may implicate problems past 3-5 years. I think the gains will be for 18 months or so which should allow some insight into the other products coming up. It shouldn't be down to this extent so as a speculative play, it surely meets sensible criteria for ka-ching in the short or medium term.